Abstract
Cutaneous bacterial infections are very common and result from bacterial invasion of the skin, near soft tissue, and its appendages. Most skin infections are caused by Staphylococcus aureus and group A β-hemolytic streptococci, with various presentations and severity. Clinical manifestations can range from mild superficial lesions to life-threatening necrotizing and systemic infections. Other bacteria can also cause skin infections with a wide variety of clinical manifestations. The diagnosis is essentially based on clinical evaluation. Cultural examinations may be necessary to confirm the etiologic agent when there is doubt about the diagnosis or there is suspicion of resistant bacteria. Management is determined by the severity and location of the infection and by patient comorbidities. Superficial uncomplicated pyodermas may be treated with topical antimicrobial drugs. Cutaneous abscesses respond well to drainage and the prescription of systemic antibiotics is generally recommended. For deep infections, the initial systemic antimicrobial treatment is empiric and generally should cover Gram-positive cocci. Patients with necrotizing infections require prompt surgical debridement and empiric polymicrobial antibiotic coverage. The antibiotic choice depends on clinical presentation and the local burden of multiresistant bacteria, mainly methicillin-resistant S. aureus.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Abbreviations
- ABSSSI:
-
Acute bacterial skin and skin structure infection
- AIDS:
-
Acquired immunodeficiency syndrome
- ASLO:
-
Antistreptolysin O
- CA-MRSA:
-
Community-associated MRSA
- FRSA:
-
Fusidic acid-resistant Staphylococcus aureus
- HA-MRSA:
-
Health- care-associated MRSA
- IDSA:
-
Infectious Diseases Society of America
- MRSA:
-
Methicillin-resistant Staphylococcus aureus
- MSSA:
-
Methicillin-susceptible Staphylococcus aureus
- SSSS:
-
Staphylococcal scalded skin syndrome
- SSTIs:
-
Bacterial skin and soft-tissue infections
- TMP-SMX:
-
Trimethoprim-sulfamethoxazole
- WHO:
-
World Health Organization
References
Dryden MS. Complicated skin and soft tissue infection. J Antimicrob Chemother. 2010;65(Suppl 3):iii35–44.
Empinotti JC, Uyeda H, Ruaro RT, Galhardo AP, Bonatto DC. Pyodermitis. An Bras Dermatol. 2012;87(2):277–84.
Stevens DL, Bryant AE. Impetigo, erysipelas and cellulitis. In: Ferretti JJ, Stevens DL, Fischetti VA, editors. Streptococcus pyogenes: basic biology to clinical manifestations [internet]. Oklahoma City: University of Oklahoma Health Sciences Center; 2016.
Falcone M, Concia E, Giusti M, Mazzone A, Santini C, Stefani S, Violi F. Acute bacterial skin and skin structure infections in internal medicine wards: old and new drugs. Intern Emerg Med. 2016;11(5):637–48.
Tognetti L, Martinelli C, Berti S, Hercogova J, Lotti T, Leoncini F, et al. Bacterial skin and soft tissue infections: review of the epidemiology, microbiology, aetiopathogenesis and treatment. A collaboration between dermatologists and infectivologists. J Eur Acad Dermatol Venereol. 2012;26(8):931–41.
Marks M, Romani L, Sokana O, et al. Prevalence of scabies and impetigo 3 years after mass drug administration with Ivermectin and azithromycin. Clin Infect Dis. 2020;70:1591.
Manders SM. Toxin-mediated streptococcal and staphylococcal disease. J Am Acad Dermatol. 1998;39(3):383–98.
Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, Hirschmann JV, Kaplan SL, Montoya JG, Wade JC. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin Infect Dis. 2014;59(2):147–59.
Russo A, Concia E, Cristini F, De Rosa FG, Esposito S, Menichetti F, Petrosillo N, Tumbarello M, Venditti M, Viale P, Viscoli C, Bassetti M. Current and future trends in antibiotic therapy of acute bacterial skin and skin-structure infections. Clin Microbiol Infect. 2016;22(Suppl 2):S27–36.
Ibrahim F, Khan T, Pujalte GG. Bacterial skin infections. Prim Care. 2015;42(4):485–99.
Vinh DC, Embil JM. Rapidly progressive soft tissue infections. Lancet Infect Dis. 2005;5:501.
Esposito S, Noviello S, Leone S. Epidemiology and microbiology of skin and soft tissue infections. Curr Opin Infect Dis Ther. 2016;29(2):109–15.
Fritz SA, Shapiro DJ, Hersh AL. National Trends in incidence of purulent skin and soft tissue infections in patients presenting to ambulatory and emergency department settings, 2000-2015. Clin Infect Dis. 2020;70:2715.
Hentges DJ. The anaerobic microflora of the human body. Clin Infect Dis. 1993;16(Suppl 4):S175–80.
Hatlen TJ, Miller LG. Staphylococcal skin and soft tissue infections. Infect Dis Clin North Am. 2021;35(1):81–105. S0891-5520(20)30082-9.
Gordon RJ, Lowy FD. Pathogenesis of methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis. 2008;46(Suppl 5):S350–9.
Bassetti M, Carnelutti A, Righi E. The role of methicillin-resistant Staphylococcus aureus in skin and soft tissue infections. Curr Opin Infect Dis. 2017;30(2):150–7.
Wertheim HF, Melles DC, Vos MC, et al. The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect Dis. 2005;5:751–62.
van Rijen M, Bonten M, Wenzel R, Klutmans J. Mupirocin ointment for preventing Staphylococcus aureus infections in nasal carriers. Cochrane Database Syst Rev. 2008;(4):CD006216.
Papastefan ST, Buonpane C, Ares G, Benyamen B, Helenowski I, Hunter CJ. Impact of decolonization protocols and recurrence in pediatric MRSA skin and soft-tissue infections. J Surg Res. 2019;242:70–7.
Al Kindi A, Alkahtani AM, Nalubega M, El-Chami C, O'Neill C, Arkwright PD, Pennock JL. Staphylococcus aureus internalized by skin keratinocytes evade antibiotic killing. Front Microbiol. 2019;10:2242.
Doudoulakakis A, Spiliopoulou I, Spyridis N, et al. Emergence of a Staphylococcus aureus clone resistant to mupirocin and fusidic acid carrying exotoxin genes and causing mainly skin infections. J Clin Microbiol. 2017;55:2529.
Natsis NE, Cohen PR. Coagulase-negative staphylococcus skin and soft tissue infections. Am J Clin Dermatol. 2018;19:671.
Lin JN, Chang LL, Lai CH, Lin HH, Chen YH. Clinical and molecular characteristics of invasive and noninvasive skin and soft tissue infections caused by group A streptococcus. J Clin Microbiol. 2011;49(10):3632–7.
Newberger R, Gupta V. Streptococcus group A. In: StatPearls [internet]. Treasure Island: StatPearls Publishing; 2020.
de Paiva Marques P, Neves PD, Mendonça HM, Fugikaha I, Fernandes EL. Acute glomerulonephritis after upper airway or skin infection: descriptive analysis of 82 cases between 14 and 64 years-old. J Bras Nefrol. 2010;32(3):237–41.
Parks T, Smeesters PR, Steer AC. Streptococcal skin infection and rheumatic heart disease. Curr Opin Infect Dis. 2012;25(2):145–53.
Siemens N, Snäll J, Svensson M, Norrby-Teglund A. Pathogenic mechanisms of streptococcal necrotizing soft tissue infections. Adv Exp Med Biol. 2020;1294:127–50.
Blaise G, Nikkels AF, Hermanns-Lê T, Nikkels-Tassoudji N, Piérard GE. Corynebacterium-associated skin infections. Int J Dermatol. 2008;47(9):884–90.
Merlino JI, Malangoni MA. Complicated skin and soft-tissue infections: diagnostic approach and empiric treatment options. Cleve Clin J Med. 2007;74:21–8.
Clebak KT, Malone MA. Skin infections. Prim Care. 2018;45(3):433–54.
Helsing P, Gaustad P. Bullous impetigo caused by group A streptococci. Acta DermVenereol (Stockh). 1992;72:50–1.
Adachi J, Endo K, Fukuzumi T, Tanigawa N, Aoki T. Increasing incidence of streptococcal impetigo in atopic dermatitis. J Dermatol Sci. 1998;17(1):45–53.
Hayakawa K, Hirahara K, Fukuda T, Okazaki M, Shiohara T. Risk factors for severe impetiginized atopic dermatitis in Japan and assessment of its microbiological features. Clin Exp Dermatol. 2009;34(5):e63–5.
Akiyama H, Yamasaki O, Kanzaki H, Tada J, Arata J. Streptococci isolated from various skin lesions: interaction with Staphylococcus aureus strains. J Dermatol Sci. 1999;19(1):7–22.
Amagai M, Matsuyoushi N, Wang ZH, et al. Toxin in bullous impetigo and staphylococcal scalded-skin syndrome targets desmoglein 1. Nat Med. 2000;6:1275–7.
Marques SA, Abbade LPF. Severe bacterial skin infections. An Bras Dermatol. 2020;95(4):407–17.
Raff AB, Kroshinsky D. Cellulitis: a review. JAMA. 2016;316(3):325–37.
Hirschmann JV, Raugi GJ. Lower limb cellulitis and its mimics: part I. Lower limb cellulitis. J Am Acad Dermatol. 2012;67:163.e1–163.e12.
Kilburn SA, Featherstone P, Higgins B, Brindle R. Interventions for cellulitis and erysipelas. Cochrane Database Syst Rev. 2010;6:CD004299.
Bruun T, Oppegaard O, Kittang BR, Mylvaganam H, Langeland N, Skrede S. Etiology of cellulitis and clinical prediction of streptococcal disease: a prospective study. Open Forum Infect Dis. 2015;3(1):ofv181.
Gunderson CG, Martinello RA. A systematic review of bacteremias in cellulitis and erysipelas. J Infect. 2012;64(2):148–55.
Bartholomeeusen S, Vandenbroucke J, Truyers C, Buntinx F. Epidemiology and comorbidity of erysipelas in primary care. Dermatology. 2007;215(2):118–22.
Quirke M, Ayoub F, McCabe A, Boland F, Smith B, O’Sullivan R, Wakai A. Risk factors for nonpurulent leg cellulitis: a systematic review and meta-analysis. Br J Dermatol. 2017;177(2):382–94.
Okajima RMO, Freitas THP, Zaitz C. Estudo clínico de 35 pacientes com diagnóstico de erisipela internados no Hospital Central da Irmandade da Santa Casa de Misericórdia de São Paulo. An Bras Dermatol. 2004;79:295–303.
Celestin R, Brown J, Kihiczak G, Schwartz RA. Erysipelas: a common potentially dangerous infection. Acta Dermatovenerol Alp Pannonica Adriat. 2007;16(3):123–7.
Ramakrishnan K, Salinas RC, Agudelo Higuita NI. Skin and soft tissue infections. Am Fam Physician. 2015;92(6):474–83.
Morris AD. Cellulitis and erysipelas. BMJ Clin Evid. 2008;2008:1708.
Danstra RJ, Van Steensel MAM, Boomsma JHB, Nelemans P, Veraart JC. Erysipelas as a sign of subclinical primary lymphoedema: a prospective quantitative scintigraphic study of 40 patients with unilateral erysipelas of the leg. Br J Dermatol. 2008;12:10–5.
Sapuła M, Krankowska D, Wiercińska-Drapało A. In search of risk factors for recurrent erysipelas and cellulitis of the lower limb: a cross-sectional study of epidemiological characteristics of patients hospitalized due to skin and soft-tissue infections. Interdiscip Perspect Infect Dis. 2020;2020:1307232.
Dalal A, Eskin-Schwartz M, Mimouni D, et al. Interventions for the prevention of recurrent erysipelas and cellulitis. Cochrane Database Syst Rev. 2017;6:CD009758.
Handler MZ, Schwartz RA. Staphylococcal scalded skin syndrome: diagnosis and management in children and adults. J Eur Acad Dermatol Venereol. 2014;28(11):1418–23.
Leung AKC, Barankin B, Leong KF. Staphylococcal-scalded skin syndrome: evaluation, diagnosis, and management. World J Pediatr. 2018;14(2):116–20.
Patel GK, Finlay AY. Staphylococcal scalded skin syndrome: diagnosis and management. Am J Clin Dermatol. 2003;4:165–75.
Durdu M, Errichetti E, Eskiocak AH, Ilkit M. High accuracy of recognition of common forms of folliculitis by dermoscopy: an observational study. J Am Acad Dermatol. 2019;81(2):463–71.
Scheinfeld N. Dissecting cellulitis (Perifolliculitis capitis Abscedens et Suffodiens): a comprehensive review focusing on new treatments and findings of the last decade with commentary comparing the therapies and causes of dissecting cellulitis to hidradenitis suppurativa. Dermatol Online J. 2014;20(5):22692.
Loayza E, Vanegas E, Cherrez A, Ojeda IC. Acne keloidalis nuchae in Latin America: is there a different phenotype? Int J Dermatol. 2017;56(12):1469–70.
Sperling LC, Homoky C, Pratt L, Sau P. Acne keloidalis is a form of primary scarring alopecia. Arch Dermatol. 2000;136(4):479–84.
Singer AJ, Thode HC Jr, Chale S, Taira BR, Lee C. Primary closure of cutaneous abscesses: a systematic review. Am J Emerg Med. 2011;29(4):361–6.
Aragüés M, González-Arriba A. Primary cutaneous infections due to staphylococcus and streptococcus. Actas Dermosifiliogr. 2007;98(Suppl 1):4–14.
Smeets L, Bous A, Heymans O. Necrotizing fasciitis: case report and review of literature. Acta Chir Belg. 2007;107:29–36.
Peetermans M, de Prost N, Eckmann C, Norrby-Teglund A, Skrede S, De Waele JJ. Necrotizing skin and soft-tissue infections in the intensive care unit. Clin Microbiol Infect. 2020;26(1):8–17.
Wróblewska M, Kuzaka B, Borkowski T, Kuzaka P, Kawecki D, Radziszewski P. Fournier’s gangrene—current concepts. Pol J Microbiol. 2014;63(3):267–73.
de Almeida HL Jr, Siqueira RN, da Silva Meireles R, Rampon G, de Castro LA, Silva RM. Pitted keratolysis. An Bras Dermatol. 2016;91(1):106–8.
Makhecha M, Dass S, Singh T, Gandhi R, Yadav T, Rathod D. Pitted keratolysis—a study of various clinical manifestations. Int J Dermatol. 2017;56(11):1154–60.
Forouzan P, Cohen PR. Erythrasma revisited: diagnosis, differential diagnoses, and comprehensive review of treatment. Cureus. 2020;12(9):e10733.
Bonifaz A, Ramírez-Ricarte I, Rodríguez-Leviz A, Hernández MA, Mena C, Valencia A. Tricomicosis (tricobacteriosis) en un infante: Aspectos microbiológicos, dermatoscópicos y ultraestructurales. Rev Chil Pediatr. 2017;88(2):258–62.
Salim G, Zahra MF. Trichobacteriosis: contribution of dermoscopy. Dermatol Online J. 2014;20(9, 13030/qt7488g7vb)
Garlicki AM, Jawień M, Pancewicz S, Moniuszko-Malinowska A, Kalinowska-Nowak A, Bociąga-Jasik M. Management of bacterial skin and soft tissue infections. Przegl Epidemiol. 2020;74(1):89–107.
Cenizal MJ, Skiest D, Luber S, et al. Prospective randomized trial of empiric therapy with trimethoprim-sulfamethoxazole or doxycycline for outpatient skin and soft tissue infections in an area of high prevalence of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2007;51:2628–30.
UK Dermatology Clinical Trials Network’s PATCH Trial Team, Thomas K, Crook A, Foster K, Mason J, Chalmers J, Bourke J, Ferguson A, Level N, Nunn A, Williams H. Prophylactic antibiotics for the prevention of cellulitis (erysipelas) of the leg: results of the UK dermatology clinical trials Network’s PATCH II trial. Br J Dermatol. 2012;166(1):169–78.
Friesen J, Neuber R, Fuhrmann J, Kietzmann H, Wenzel T, Schaumburg F, Müller M, Ignatius R. Panton-Valentine leukocidin-positive Staphylococcus aureus in skin and soft tissue infections from primary care patients. Clin Microbiol Infect. 2020;26(10):1416.e1–4.
Principi N, Argentiero A, Neglia C, Gramegna A, Esposito S. New antibiotics for the treatment of acute bacterial skin and soft tissue infections in pediatrics. Pharmaceuticals (Basel). 2020;13(11):333.
Monteagudo-Martínez N, Solís-García Del Pozo J, Nava E, Ikuta I, Galindo M, Jordán J. Acute bacterial skin and skin-structure infections, efficacy of Dalbavancin: a systematic review and meta-analysis. Expert Rev Anti Infect Ther. 2020;21:1–13.
Lan SH, Lin WT, Chang SP, Lu LC, Chao CM, Lai CC, Wang JH. Tedizolid versus linezolid for the treatment of acute bacterial skin and skin structure infection: a systematic review and meta-analysis. Antibiotics (Basel). 2019;8(3):137.
Corey GR, McKinnell JA, Rybak MJ. Delafloxacin in acute bacterial skin and skin structure infections. Clin Infect Dis. 2019;68(Suppl 3):S191–2.
Abrahamian FM, Sakoulas G, Tzanis E, Manley A, Steenbergen J, Das AF, Eckburg PB, McGovern PC. Omadacycline for acute bacterial skin and skin structure infections. Clin Infect Dis. 2019;69(Suppl 1):S23–32.
Lio PA, Kaye ET. Topical antibacterial agents. Med Clin North Am. 2011;95(4):703–21. vii.
Koning S, van der Sande R, Verhagen AP, van Suijlekom-Smit LW, Morris AD, Butler CC, Berger M, van der Wouden JC. Interventions for impetigo. Cochrane Database Syst Rev. 2012;(1):CD003261.
Nagabushan H. Retapamulin: a novel topical antibiotic. Indian J Dermatol Venereol Leprol. 2010;76(1):77–9.
Williamson DA, Monecke S, Heffernan H, Ritchie SR, Roberts SA, Upton A, Thomas MG, Fraser JD. High usage of topical fusidic acid and rapid clonal expansion of fusidic acid-resistant Staphylococcus aureus: a cautionary tale. Clin Infect Dis. 2014;59(10):1451–4.
Rosen T, Albareda N, Rosenberg N, et al. Efficacy and safety of Ozenoxacin cream for treatment of adult and pediatric patients with impetigo: a randomized clinical trial. JAMA Dermatol. 2018;154:806.
May P, Bowen A, Tong S, Steer A, Prince S, Andrews R, Currie B, Carapetis J. Protocol for the systematic review of the prevention, treatment and public health management of impetigo, scabies and fungal skin infections in resource-limited settings. Syst Rev. 2016;5(1):162.
Marks M, Toloka H, Baker C, et al. Randomized trial of community treatment with azithromycin and ivermectin mass drug administration for control of scabies and impetigo. Clin Infect Dis. 2019;68:927.
Galli L, Venturini E, Bassi A, Gattinara GC, Chiappini E, Defilippi C, Diociaiuti A, Esposito S, Garazzino S, Giannattasio A, Krzysztofiak A, Latorre S, Lo Vecchio A, Marchisio P, Montagnani C, Nicolini G, Novelli A, Rossolini GM, Tersigni C, Villani A, El Hachem M, Neri I, Italian Pediatric Infectious Diseases Society; Italian Pediatric Dermatology Society. Common community-acquired bacterial skin and soft-tissue infections in children: an intersociety consensus on impetigo, abscess, and cellulitis treatment. Clin Ther. 2019;41(3):532–551.e17.
British Lymphology Society (BLS). Consensus document on the management of cellulitis in lymphoedema. Revised cellulitis guidelines 2016 [internet]. https://www.lymphoedema.org/wp-content/uploads/2020/01/cellulitis_consensus.pdf. Accessed Jan 2020.
Forcade NA, Wiederhold NP, Ryan L, Talbert RL, Frei CR. Antibacterials as adjuncts to incision and drainage for adults with purulent methicillin-resistant Staphylococcus aureus (MRSA) skin infections. Drugs. 2012;72(3):339–51.
Talan DA, Mower WR, Krishnadasan A, Abrahamian FM, Lovecchio F, Karras DJ, Steele MT, Rothman RE, Hoagland R, Moran GJ. Trimethoprim-sulfamethoxazole versus placebo for uncomplicated skin abscess. N Engl J Med. 2016;374(9):823–32.
Daum RS, Miller LG, Immergluck L, Fritz S, Creech CB, Young D, Kumar N, Downing M, Pettibone S, Hoagland R, Eells SJ, Boyle MG, Parker TC, Chambers HF, DMID 07-0051 Team. A placebo-controlled trial of antibiotics for smaller skin abscesses. N Engl J Med. 2017;376(26):2545–55.
Gottlieb M, DeMott JM, Hallock M, Peksa GD. Systemic antibiotics for the treatment of skin and soft tissue abscesses: a systematic review and meta-analysis. Ann Emerg Med. 2019;73:8.
Burnham JP, Kollef MH. Treatment of severe skin and soft tissue infections: a review. Curr Opin Infect Dis. 2018;31(2):113–9.
Fisher A, Webber BJ, Pawlak MT, Johnston L, Tchandja JB, Yun H. Epidemiology, microbiology, and antibiotic susceptibility patterns of skin and soft tissue infections, Joint Base San Antonio-Lackland, Texas, 2012–2014. MSMR. 2015;22(7):2–6.
Further Readings
American Academy of Pediatrics. In: Kimberlin DW, Brady MT, Jackson MA, Long SS, editors. Red book: 2018. Report of the committee on infectious diseases. 31th ed. Elk Grove Village; 2018. http://redbook.solutions.aap.org/redbook.aspx.
Bennett JE, Dolin R, Blaser MJ, editors. Mandell, Douglas and Bennett’s principles & practice of infectious diseases. 9th ed. Philadelphia: Churchill Livingstone; 2019. Traditional book with comprehensive approach to infectious diseases.
Infectious Diseases Society of America. Practice guidelines. n.d.. https://www.idsociety.org/practice-guideline/practice-guidelines.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Glossary
- Abscess
-
Pus collections in dermis or deeper tissues.
- Acne keloidalis nuchae
-
A chronic pattern of deep folliculitis of the scalp that occurs in the lower occipital region and leads to scarring alopecia with keloid formation.
- Bacteremia
-
Presence of viable bacteria in the bloodstream.
- β-lactams
-
A class of broad-spectrum antibiotics, such as the penicillins and the cephalosporins, that chemically contain a β-lactam ring.
- Carbapenems
-
A class of β-lactam antibiotics highly resistant to β-lactamases.
- Carbuncles
-
Furuncle aggregates that form large, painful inflammatory masses.
- Ceftaroline fosamil
-
A fifth-generation cephalosporin (antibiotic).
- Ceftriaxone
-
A third-generation cephalosporin (antibiotic).
- Cellulitis
-
Deep skin infection that involves the dermis and subcutaneous tissue associated with severe pain and systemic symptoms.
- Cephalexin:
-
A first-generation cephalosporin (antibiotic).
- Cephalosporins
-
A class of β-lactam antibiotics originally isolated from the fungus Cephalosporium acremonium. Successive generations have different antimicrobial spectra: the newer are more active against Gram-negative bacteria.
- Clindamycin
-
A semisynthetic antibiotic, derived from lincomycin and active against Gram-positive and anaerobic bacteria.
- Dalbavancin
-
A lipoglycopeptide antibiotic with extremely long half-life and activity against the gram-positive pathogens including MRSA.
- Daptomycin
-
A cyclic lipopeptide parenteral antibiotic with bactericidal activity against a wide range of Gram-positive bacteria, including S. aureus resistant to methicillin and vancomycin. The mechanism of action involves disruption of the bacterial cytoplasmic membrane and inhibition of protein and nucleic acids synthesis.
- Delafloxacin
-
An anionic fluoroquinolone active against several gram-positive and gram-negative bacteria
- Dicloxacillin
-
A semisynthetic penicillinase-resistant penicillin.
- Dissecting cellulitis
-
Also known as perifolliculitis capitis abscedens et suffodiens, it is a clinical form of chronic folliculitis of the scalp that manifests with pus collections, sinuses, and scarring alopecia.
- Ecthyma
-
Bacterial skin infection that reaches the superficial dermis. The main etiologic agents are S. aureus and S. pyogenes.
- Elephantiasis nostra
-
Chronic lymphatic swelling of lower limbs leading to skin tightening and hyperkeratosis, induced by recurrent erysipelas that damage lymphatic vessels.
- Erysipelas
-
Deep skin infection considered a specific type of cellulitis that involves superficial dermal structures and is distinguished clinically by its well-demarcated raised borders.
- Erythromycin
-
A macrolide antibiotic, obtained from the actinomycete Streptomyces erythraeus.
- Fluoroquinolones
-
A subgroup of quinolones, antibiotics with broad spectrum of antimicrobial activity that inhibit bacterial DNA gyrase.
- Folliculitis
-
Inflammation of the hair follicle, associated with multiple causes. Infectious folliculitis is most commonly caused by S. aureus. It can be classified into superficial and deep folliculitis.
- Folliculitis decalvans
-
Specific form of chronic deep folliculitis of the scalp usually associated with S. aureus and leading to scarring alopecia.
- Fournier’s gangrene
-
A clinical form of necrotizing fasciitis of the perineal, genital, or perianal regions.
- Furuncle
-
Also known as a “boil,” the deep form of folliculitis that manifests clinically as tender inflammatory papules or nodules.
- Fusidic acid
-
Antibiotic derived from the fungus Fusidium coccineum that interferes with the bacterial protein synthesis by preventing translocation elongation factor G (EF-G) of the ribosome. It is only active against Gram-positive bacteria such as Staphylococcus and can be topically or systemically administered.
- Impetigo
-
Bacterial skin infection limited to the superficial layers of the epidermis, caused by S. aureus and S. pyogenes.
- Intertrigo
-
An inflammatory process in skin folds, induced or aggravated by heat, moisture, maceration, friction, and microbial proliferation.
- Linezolid
-
A synthetic antibiotic of the oxazolidinone class that prevents formation of essential component of bacterial protein synthesis.
- Lymphedema
-
Accumulation of lymphatic fluid in the interstitial tissues of the body with accompanying swelling, often of the extremities, caused by damage in lymphatic vessels or lymph nodes.
- Macrolide
-
A class of broad-spectrum antibiotics that chemically contain a large lactone ring and act by inhibiting protein synthesis.
- Metronidazole
-
A synthetic antiprotozoal and antibacterial drug that is effective against obligate anaerobes.
- Mupirocin
-
Topical antibiotic with bactericidal activity, derived from Pseudomonas fluorescens. Its particular mechanism of action results from inhibition of transfer RNA and is not related to any other antibacterial. It is indicated for the treatment of skin infections by Gram-positive organisms, especially S. aureus, and is often formulated in cream or ointment at 2%.
- Necrotizing fasciitis
-
Deep bacterial infection that extends rapidly along the superficial fascia and subcutaneous tissue planes, resulting in soft tissue necrosis and systemic toxicity.
- Omadacycline
-
Novel semisynthetic tetracycline active against some Gram-negative rods; atypical bacteria; and several multidrug-resistant Gram-positive organisms, including MRSA.
- Oritavancin
-
A lipoglycopeptide antibiotic with extremely long half-life and activity against the gram-positive pathogens including MRSA.
- Ozenoxacin
-
A new nonfluorinated quinolone for topical use.
- Penicillins
-
A class of β-lactam antibiotics that were originally isolated from the fungus of the genus Penicillium and later gave rise to the various semisynthetic antimicrobials.
- Piperacillin-tazobactam
-
A β-lactam antibiotic associated with a β-lactamase inhibitor.
- Poststreptococcal glomerulonephritis (PSGN)
-
Acute glomerulonephritis (glomeruli inflammation) following streptococcal infection and characterized by sudden appearance of hematuria, proteinuria, edema, and hypertension.
- Retapamulin
-
Topical antibiotic with in vitro and in vivo activity against S. aureus (including MRSA) and S. pyogenes and poor activity against Gram-negative bacteria. It is a semisynthetic derivative of pleuromutilin compound derived from the fungus Clitopilus passeckerianus and inhibits bacterial protein synthesis but binds at a different site on the 50S subunit of the bacterial ribosome.
- Rheumatic fever
-
Inflammatory systemic disease induced by toxins produced by certain strains of group A streptococci. The most characteristic findings are fever, migratory arthritis, neurologic manifestations, and permanent damage to the heart structures.
- Ritter disease
-
Also known as staphylococcal scalded skin syndrome, it is characterized by diffuse epidermal detachment caused by exfoliative exotoxins produced by S. aureus.
- Scarlet fever
-
A bacterial illness that develops in some people who have strep throat. Also known as scarlatina, scarlet fever features a bright red rash that covers most of the body. Scarlet fever is almost always accompanied by a sore throat and a high fever.
- Sepsis
-
Systemic inflammatory response to infection.
- Staphylococcal scalded skin syndrome (SSSS)
-
See “Ritter disease.”
- Streptolysin O
-
A hemolysin produced by β-hemolytic streptococci. The laboratory titration of antistreptolysin O antibody (ASLO) is used as a diagnostic tool of recent streptococcal infection.
- Sycosis
-
Etymologically, the term refers to an inflammatory process in hair follicles. However, it is most commonly used to describe a chronic deep folliculitis, most commonly in the beard region, caused by staphylococcal infection.
- Tedizolid
-
A novel oxazolidinone antibiotic safer, less expensive and significantly more effective than linezolid against MSSA, MRSA, and even vancomycin-resistant S. aureus.
- Teicoplanin
-
A glycopeptide antibiotic highly effective against Gram-positive bacteria, especially against staphylococci.
- Tetracyclines
-
A class of antibiotics effective against a wide variety of organisms, acting by inhibiting protein synthesis.
- Tigecycline
-
The first drug in the glycylcycline class of antibiotics, which acts by inhibiting protein synthesis.
- Trimethoprim-sulfamethoxazole (TMP-SMX)
-
Also known as co-trimoxazole, it is a broad-spectrum combination antibiotic. The drug combination is synergistic as the drugs interfere with two successive steps in the formation/utilization of folic acid by microorganisms.
- Vancomycin
-
A glycopeptide antibiotic highly effective against Gram-positive bacteria, especially staphylococci.
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Bessa, G. (2023). Bacterial Infections. In: Rangel Bonamigo, R. (eds) Dermatology in Public Health Environments. Springer, Cham. https://doi.org/10.1007/978-3-031-13505-7_9
Download citation
DOI: https://doi.org/10.1007/978-3-031-13505-7_9
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-13504-0
Online ISBN: 978-3-031-13505-7
eBook Packages: MedicineMedicine (R0)